Kuros Biosciences AG
SIX:KURN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aavas Financiers Ltd
BSE:541988
|
IN |
|
Daimler AG
XETRA:DAI
|
DE |
|
W
|
Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871
|
CN |
|
Unieuro SpA
MIL:UNIR
|
IT |
|
A
|
Antong Holdings Co Ltd
SSE:600179
|
CN |
|
S
|
Shanghai Rendu Biotechnology Co Ltd
SSE:688193
|
CN |
|
H
|
Hardwyn India Ltd
NSE:HARDWYN
|
IN |
|
Coor Service Management Holding AB
STO:COOR
|
SE |
|
Leo Group Co Ltd
SZSE:002131
|
CN |
|
Shanghai Yongguan Adhesive Products Corp Ltd
SSE:603681
|
CN |
Kuros Biosciences AG
Intangible Assets
Kuros Biosciences AG
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kuros Biosciences AG
SIX:KURN
|
Intangible Assets
CHf16.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Intangible Assets
CHf371k
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
2%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Intangible Assets
CHf29.6m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Intangible Assets
CHf30.6m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
Glance View
Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
See Also
What is Kuros Biosciences AG's Intangible Assets?
Intangible Assets
16.6m
CHF
Based on the financial report for Dec 31, 2025, Kuros Biosciences AG's Intangible Assets amounts to 16.6m CHF.
What is Kuros Biosciences AG's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
-7%
Over the last year, the Intangible Assets growth was -12%. The average annual Intangible Assets growth rates for Kuros Biosciences AG have been -5% over the past three years , -7% over the past five years .
